Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association
Thomas A. Pearson,George A. Mensah,R. Wayne Alexander,Jeffrey L. Anderson,Richard O. Cannon,Michael H. Criqui,Yazid Y. Fadl,Stephen P. Fortmann,Yuling Hong,Gary L. Myers,Nader Rifai,Sidney C. Smith,Kathryn A. Taubert,Russell P. Tracy,Frank Vinicor +14 more
Reads0
Chats0
TLDR
There has been no consensus from professional societies or governmental agencies as to how these assays of markers of inflammation should be used in clinical practice, and a workshop to address these issues was convened in Atlanta, Ga.Abstract:
In 1998, the American Heart Association convened Prevention Conference V to examine strategies for the identification of high-risk patients who need primary prevention. Among the strategies discussed was the measurement of markers of inflammation.1 The Conference concluded that “many of these markers (including inflammatory markers) are not yet considered applicable for routine risk assessment because of: (1) lack of measurement standardization, (2) lack of consistency in epidemiological findings from prospective studies with endpoints, and (3) lack of evidence that the novel marker adds to risk prediction over and above that already achievable through the use of established risk factors.” The National Cholesterol Education Program Adult Treatment Panel III Guidelines identified these markers as emerging risk factors,1a which could be used as an optional risk factor measurement to adjust estimates of absolute risk obtained using standard risk factors. Since these publications, a large number of peer-reviewed scientific reports have been published relating inflammatory markers to cardiovascular disease (CVD). Several commercial assays for inflammatory markers have become available. As a consequence of the expanding research base and availability of assays, the number of inflammatory marker tests ordered by clinicians for CVD risk prediction has grown rapidly. Despite this, there has been no consensus from professional societies or governmental agencies as to how these assays of markers of inflammation should be used in clinical practice.
On March 14 and 15, 2002, a workshop titled “CDC/AHA Workshop on Inflammatory Markers and Cardiovascular Disease: Applications to Clinical and Public Health Practice” was convened in Atlanta, Ga, to address these issues. The goals of this workshop were to determine which of the currently available tests should be used; what results should be used to define high risk; which patients should be tested; and the indications for which the tests would be most useful. These …read more
Citations
More filters
Journal ArticleDOI
Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study.
Renate B. Schnabel,Hans J. Rupprecht,Karl J. Lackner,Edith Lubos,Christoph Bickel,Jürgen Meyer,Thomas Münzel,François Cambien,Laurence Tiret,Stefan Blankenberg,Stefan Blankenberg +10 more
TL;DR: Baseline concentration of Nt-proBNP is independently related to future cardiovascular events in patients with stable angina, and remained predictive for patients with serum concentrations in the upper quartile in comparison with patients in the lowest quartile.
Journal ArticleDOI
Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function.
Vittorio Schiano,Eugenio Laurenzano,Gregorio Brevetti,Julieta Isabel De Maio,Simona Lanero,Francesco Scopacasa,Massimo Chiariello +6 more
TL;DR: In PAD, n-3 PUFAs induced a marked improvement in endothelial function, and they did not affect the inflammatory status, which is likely to reduce the incidence of ischemic events in a population at high risk.
Journal ArticleDOI
Therapeutic Strategies for Treatment of Inflammation-related Depression
Miroslav Adzic,Zeljka Brkic,Milos Mitic,Ester Francija,Milica Jovicic,Jelena Radulovic,Nadja P. Maric +6 more
TL;DR: Anti-inflammatory add-on therapy in depression highlights such treatment as a candidate for enhancement strategy in patients with moderate-to-severe depression, and the interactions between the immune system and CNS are not only involved in shaping behavior, but also in responding to therapeutics.
Journal ArticleDOI
High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study
Michiel J. Bos,C. Maarten A. Schipper,Peter J. Koudstaal,Jacqueline C.M. Witteman,Albert Hofman,Monique M.B. Breteler +5 more
TL;DR: Taking CRP levels into account did not improve the individual stroke risk prediction, however, regardless of whether it was based on the Framingham stroke risk score or on age and sex only.
Journal ArticleDOI
Relation between C reactive protein concentrations and coronary microvascular endothelial function.
Hiroki Teragawa,Yukihiro Fukuda,K Matsuda,Keiko Ueda,Yukihito Higashi,Tetsuya Oshima,Masao Yoshizumi,Kazuaki Chayama +7 more
TL;DR: It is suggested that inflammation appears to be associated with impaired coronary endothelial function in resistance but not conduit vessels, and a close relation between chronic vascular inflammation and endothelial dysfunction in atherosclerosis is suggested.
References
More filters
Journal ArticleDOI
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Journal ArticleDOI
Atherosclerosis — An Inflammatory Disease
TL;DR: Atherosclerosis is an inflammatory disease as discussed by the authors, and it is a major cause of death in the United States, Europe, and much of Asia, despite changes in lifestyle and use of new pharmacologic approaches to lower plasma cholesterol concentrations.
Journal ArticleDOI
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen B. Hulley,Deborah Grady,Trudy L. Bush,Curt D Furberg,David M. Herrington,Betty Riggs,Eric Vittinghoff +6 more
TL;DR: Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.
Journal ArticleDOI
C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
TL;DR: The addition of the measurement of C-reactive protein to screening based on lipid levels may provide an improved method of identifying persons at risk for cardiovascular events.
Related Papers (5)
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more